Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.

Patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are at high risk of developing bacterial infections. These patients may suffer severe consequences from these infections if they do not receive immediate effective therapies, and thus are uniquely threatened by antimicrobial-resistant bacteria. Here, we outline how the emergence of specific resistant bacteria threatens the effectiveness of established approaches to prevent and treat infections in this population.

Corrigendum to: Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male.

[This corrects the article DOI: 10.1093/ofid/ofab455.].

Impact of a Multiplex Polymerase Chain Reaction Panel on Duration of Empiric Antibiotic Therapy in Suspected Bacterial Meningitis.

Background: Multiplex polymerase chain reaction (PCR) panels allow for rapid detection or exclusion of pathogens causing meningitis and encephalitis (ME). The clinical impact of rapid multiplex PCR ME panel results on the duration of empiric antibiotic therapy is not well characterized.

Methods: We performed a retrospective prepost study at our institution that evaluated the clinical impact of a multiplex PCR ME panel among adults with suspected bacterial meningitis who received empiric antibiotic therapy and underwent lumbar puncture in the emergency department.

Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male.

We present a case of a human immunodeficiency virus-negative man with syphilitic meningovascular disease with subjacent involvement of brain parenchyma leading to a mass-forming inflammatory lesion that was pathologically distinct from a typical gumma. Syphilis was diagnosed after tissue obtained from a brain biopsy demonstrated spirochetes consistent with and confirmed by 16S ribosomal RNA sequencing.

Rates of Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an -Amplified Acral Melanoma.

Purpose: Patients with V600 wild-type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. alterations may be amenable to targeted inhibition, but the rate of alterations across melanoma subtypes is not well described.

Patients And Methods: All patients with nonuveal melanoma (cutaneous, acral, mucosal, and unknown primary) whose tumors underwent multigene sequencing with MSK-IMPACT at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 to 2018 were reviewed for known or likely oncogenic somatic alterations in and the other known canonical driver genes , and .